Makers Laboratories Reports Profit Turnaround in Q2

Revenue: Rs 48.21 crore (Q2 FY27) vs Rs 34.17 crore (Q2 FY26)
Net Profit: Rs 3.95 crore (Q2 FY27) vs Net Loss of Rs 0.12 crore (Q2 FY26)

Reader Takeaway: Strong chemical segment performance drove the profit turnaround; sustained margins and segment growth remain key focus areas.

What just happened

Makers Laboratories has released its unaudited financial results for the quarter and half-year ended September 30, 2026. The company achieved a successful swing back to profitability, reporting a consolidated net profit of Rs 3.95 crore, compared to a net loss of Rs 0.12 crore in the corresponding quarter of the previous fiscal year. Revenue from operations also saw a significant boost, climbing to Rs 48.21 crore from Rs 34.17 crore year-on-year.

Why this matters

The growth was powered by the chemical manufacturing division, which saw revenue rise to Rs 35.03 crore, generating a PBT of Rs 11.19 crore. The pharmaceutical segment also showed steady activity, reporting revenue of Rs 13.93 crore. The auditor, NVC & Associates LLP, issued an unmodified review report, providing assurance to investors regarding the accuracy of the financial statements.

What to track next

Investors should look for signs of margin sustainability in the chemical manufacturing segment, as this remains the primary driver of the company’s current profitability. Monitoring whether the pharmaceutical segment can scale its contribution in upcoming quarters will also be critical for long-term growth.